ASCO 2026 | The potential of cell therapies in the treatment of head and neck cancer
Kedar Kirtane
• 30 May 2026
Kedar Kirtane, MD, Moffitt Cancer Center, Tampa, FL, discusses the potential of emerging cell therapies, including tumor-infiltrating lymphocytes (TILs), CAR-Ts, and T cell receptors (TCRs), in the treatment of head and neck cancer, highlighting the need for innovative approaches to improve outcomes for patients with metastatic disease who have limited treatment options. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
